Endometrial cancer

Onkologie

Volumn 26, Issue 5, 2003, Pages 429-436

  Hanf, V ^a   Gunthert A R ^a   Emons, G ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Adjuvant therapy; Chemotherapy; Endocrine therapy; Endometrial cancer; Palliative therapy; Surgical staging

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FULVESTRANT; GESTAGEN; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; BLOOD TOXICITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; ENDOMETRIUM CARCINOMA; HORMONAL THERAPY; HUMAN; LYMPHADENECTOMY; METABOLIC DISORDER; METASTASIS; PALLIATIVE THERAPY; PARAAORTIC LYMPH NODE; PELVIS; RADIATION RESPONSE; REVIEW; SIDE EFFECT; TOXICITY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VASCULAR DISEASE;

COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS;

EID: 0242544070     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072975     Document Type: Review

References (34)

1. Parazzini F, La Vecchia C, Bocciolone L, Francheschi S: The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
2. Barakat RR: Contemporary Management of Endometrial Cancer, Educational Book. Orlando, FL, American Society of Clinical Oncology, 2002, pp 85-88.
3. Emons G, Günthert A, Viereck V, Hanf V: Endocrine therapy of endometrial cancer and endometrial hyperplasia. Gynäkologe 2003;36:86-96.
4. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W: Hormonal interactions in endometrial cancer. Endocrine Related Cancer 2000;7:227-242.
5. Sehouli J, Camara O, Stengel D, Kohler G, Lichtenegger W: Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany. Gynäkol Geburtshilfliche Rundsch 2003;43:104-110.
6. Creutzberg CL, van Putten WLJ, Koper PCM, Lybeert MLM, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van de Steen-Banasik E, Beerman H, van Lent M, for the PORTEC Study Group: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. Lancet 2000;355:1404-1411.
7. Ackerman I, Malone S, Thomas G, Franssen E, Balogh J, Dembo A: Endometrial carcinoma relative effectiveness of adjuvant irradiation vs. therapy reserved for relapse. Gynecol Oncol 1996;60:177-183.
8. Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, Zanagnolo V: Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 2001;11:430-437.
9. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, Conner W: Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33.
10. COSA-NZ-UK-Endometrial Cancer Study Groups: Pelvic lymphadenectomy in high risk endometrial cancer. Int J Gynecol Cancer 1996;6:102-107.
11. Fanning J: Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001;371-374.
12. Larson DM, Broste SK, Krawisz BR: Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol 1998;91:355-359.
13. Orr JW, Roland PY, Leichter D, Orr PF: Endometrial cancer: Is surgical staging necessary? Curr Opin Oncol 2001;13:408-412.
14. Seago DP, Raman A, Lele S: Potential benefit of lymphadenectomy for the treatment of node-negative locally advanced uterine cancers. Gynecol Oncol 2001;83:282-285.
15. Irvin WP, Rice LW: Advances in the management of endometrial adenocarcinoma. J Reprod Med 2002;47:173-189.
16. Mariani A, Webb MJ, Galli L, Podratz KC: Potential therapeutic role of paraaortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 2000;76:348-356.
17. McMeekin DS, Lashbrook D, Gold M, Scribner DR, Kamelle S, Tillmanns TD, Mannel R: Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol 2001;82:375-379.
18. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AMP, Ngan HYS, Sideri M, Pecorelli S: Carcinoma of the corpus uteri - annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat 2001;6:45-86.
19. Arango HA, Hoffman MS, Roberts WS, DeCesare SL, Fiorica JV, Drake J: Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. Obstet Gynecol 2000;95:553-556.
20. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC: Role of wide/ radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol 2001;83:72-80.
21. Ayhan A, Taskiran C, Celik C, Yuce K, Kucukali T: The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int J Gynecol Cancer 2002;12:448-453.
22. Aalders J, Abeler V, Kolstad P, Onsrud M: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 1980;56:419-426.
23. Greven KM: Options for Adjuvant Therapy in the Treatment of Endometrial Cancer, Educational Book. Orlando, FL, American Society for Clinical Oncology, 2002, pp 98-103.
24. Axelrod J, Bundy B, Roy: Advanced endometrial carcinoma treated with whole abdominal irradiation:A Gynecologic Oncology Group study. Proc Soc Gynecol Oncol 1995;135-136.
25. Randall ME, Brunetto G, Muss H, Mannel RS, Spirtos N, Jeffrey F, Thigpen JT, Benda J: Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynaecologic Oncology Group. ASCO 2003;22:Abstr 3.
26. Dt. Krebsgesellschaft: Kurzgefasste Interdisziplinäre Leitlinien 2002, 3. Auflage AWMF-Leitlinien-Register Nr. 032/034 Entwicklungsstufe: 1; http://www.uni-duesseldorf.de/AWMF/ll/index.html.
27. Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R: Progestagens for endometrial cancer (Cochrane Review); in Cochrane Library, Issue 4, Oxford, Updated Software 2002.
28. von Minckwitz G, Loibl S, Brunnert K, Kreienberg R, Melchert F, Mosch R, Neises M, Schermann J, Seufert R, Stiglmayer R, Stosiek U, Kaufmann M: Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer - a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 2002;38:2265-2271.
29. Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, Lai CH: Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002;94:2192-2198.
30. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HP, Manetta A, Soper JT, Given FT: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736-1744.
31. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C: A randomized comparison of doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408-1414.
32. Fleming G, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball G, McGuire III WP: Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: A Gynecologic Oncology Group study. J Clin Oncol 2001;19:1021-1029.
33. Fleming GF, Brunetto VL, Mundt AJ, Burks RT, Look KY, Reid G: Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 2002;21:202a.
34. Günthert AR, Pilz S, Kuhn W, Emons G, Meden H: Docetaxel is effective in the treatment of metastatic endometrial cancer. Anticancer Res 1999;19:3459-3462.